Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2460585 | 0.80 | PDE10A (0.40) | PDE10AP2RX7OPRL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL15205058 | 0.76 | HCRTR2 (0.37) | PDE10AOPRL1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL14878667 | 0.70 | PDE10A (0.58) | PDE10A | |
| SCHEMBL1009179 | 0.69 | LMNA (0.35) | SMN1; SMN2ALDH1A1LMNAPDK2 | |
| SCHEMBL29142176 | 0.68 | LMNA (0.36) | SMN1; SMN2LMNAPDK2 | |
| SCHEMBL1994153 | 0.67 | TDP1 (0.35) | P2RX7SMN1; SMN2ALDH1A1LMNAPDK2 | |
| SCHEMBL2457709 | 0.67 | PDK2 (0.41) | PDE10AALDH1A1PDK2 | |
| SCHEMBL10640693 | 0.66 | BDKRB1 (0.36) | SMN1; SMN2LMNAOPRM1 | |
| SCHEMBL27775621 | 0.66 | SMN1; SMN2 (0.38) | P2RX7SMN1; SMN2ALDH1A1LMNAPDK2 | |
| SCHEMBL2461591 | 0.65 | PDE10A (0.42) | PDE10AP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759532-B2 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2364306-B1 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | AMGEN INC (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-2364306-B1 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | AMGEN INC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20130079325-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | ALLEN JENNIFER R (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130079325-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | ALLEN JENNIFER R (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130079325-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | ALLEN JENNIFER R (US) | 2013-03-28 | — | — | US | disclosed |
| US-8318718-B2 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318718-B2 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318718-B2 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2364306-A1 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | Amgen Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMEN INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMEN INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMEN INC. (US) | 2010-05-20 | — | — | US | disclosed |
| WO-2010057126-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010057126-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079325-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | PDE7A, PDE9A, PDE10A | PDE10A 3/4885P2RX7 183/4885OPRL1 2652/4885 |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | PDE7A, PDE9A, PDE10A | PDE10A 3/4885P2RX7 183/4885OPRL1 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.